Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data 20/20 Biolabs, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Revenue
1.75
2.05
Cost of revenue
1.39
1.44
Gross profit
0.36
0.6
Research and development
1.26
0.59
Selling, general and administrative
4.76
3.34
Operating expenses
6.04
3.94
Operating income
-5.68
-3.33
Interest expense
0.01
0.16
Interest income
0.08
0.02
Other non-operating income
0.13
-0.41
Net income
-5.55
-3.74
EBITDA
-5.56
-3.27
EPS, basic
-1.16
-0.76
EPS, diluted
-1.16
-0.76
Shares, basic (weighted)
4.8
4.93
Shares, diluted (weighted)
4.8
4.93
Balance sheet
FY2025
FY2025
Cash and equivalents
1.78
1.03
Receivables
0.14
0.2
Inventory
0.05
0.12
Other current assets
0.07
0.13
Total current assets
2.03
1.47
Property, plant and equipment
0.12
0.06
Lease right-of-use assets
0.77
0.61
Intangible assets
0.21
0.2
Other non-current assets
0.16
0.02
Total assets
3.58
4.14
Accounts payable
0.37
0.87
Accrued liabilities
0.35
0.79
Deferred revenue
0.47
0.41
Total current liabilities
1.36
2.46
Lease liabilities
0.67
0.49
Total liabilities
2.08
4.16
Paid-in capital
30.9
33.1
Retained earnings
-29.5
-33.2
Shareholders' equity
1.51
-0.02
Total equity
1.51
-0.02
Total liabilities and equity
3.58
4.14
Shares outstanding
4.82
5.44
Cash flow statement
FY2025
FY2025
Net income
-5.55
-3.74
Depreciation and amortization
0.12
0.06
Stock-based compensation
2.18
0.52
Change in receivables
-0.07
-0.06
Change in inventory
0.01
-0.07
Change in payables
0.01
0.5
Cash from operations
-2.6
-1.92
Cash from financing
0.29
1.16
Net change in cash
-2.31
-0.76
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.22 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
29.6%
Gross profit / revenue.
Operating margin
-162.9%
Operating income / revenue.
EBITDA margin
-159.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-182.8%
Net income / revenue.
Operating cash flow margin
-93.9%
Cash from operations / revenue.
Return on assets (ROA)
-96.8%
Net income / average total assets.
R&D / revenue
29.0%
Research and development expense / revenue.
SG&A / revenue
163.5%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
25.2%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
3.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
16.7%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
67.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-101.3%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
15.4%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
2.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.60x
Current assets / current liabilities.
Quick ratio
0.50x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.42x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.76
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.76
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.41
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.39
Cash from operations / diluted weighted shares.
Book value per share
-$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.40x
Market cap / revenue.
EV/Sales
0.90x
Enterprise value / revenue.
Earnings yield
-130.2%
Net income / market cap (the inverse of P/E).
What was 20/20 Biolabs, Inc.'s revenue in fiscal 2025?
20/20 Biolabs, Inc. reported revenue of $2.0M for fiscal 2025, 16.7% higher than the year before.
Was 20/20 Biolabs, Inc. profitable in fiscal 2025?
No. It reported a net loss of $3.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.